Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to increase public awareness of (a) which medicines are known to have teratogenous effects and (b) the risks of taking teratogenous medicines during pregnancy.

The product information for each medicine possibly associated with teratogenic effects includes details about the nature and severity of the risk. The product information is intended to support and not replace the discussion between a healthcare professional and their patient regarding their treatment options.

The Medicines and Healthcare products Regulatory Agency continuously monitors the safety of medicines, including their use during pregnancy, ensuring the product information reflects what is known about each medicine.